Table 4.

Treatment outcome after the grouping

	EG,n/N(%)	CG,n/N(%)	p -value
Stage IIB and IIIB
Overall recurrence	13/49 (26.5%)	17/34 (50%)	0.029
In-field recurrence	6/49 (12.2%)	12/34 (35.3%)	0.012
Out-field recurrence	9/49 (18.4%)	16/34 (47.1%)	0.005
Stage IIIC1
Total recurrence	11/54 (20.4%)	18/42 (42.9%)	0.017
In-field recurrence	7/54 (13.0%)	14/42 (33.3%)	0.017
Out-field recurrence	4/54 (7.4%)	9/42 (21.4%)	0.046
Stage IIIC2
Total recurrence	5/9 (55.6%)	10/15 (66.7%)	0.687
In-field recurrence	4/9 (44.4%)	8/15 (53.3%)	1
Out-field recurrence	2/9 (22.2%)	7/15 (46.7%)	0.389
Stage IVA
Total recurrence	2/7(28.6%)	4/7 (57.1%)	0.592
In-field recurrence	1/7 (14.3%)	2/7 (28.6%)	1
Out-field recurrence	1/7(14.3%)	3/7(42.9%)	0.559

EG The experimental group, CG The control group